A Desktop Primer and Practical Review of Cannabis-Containing
Compounds and Their Entourage Effects

Nicholas A Kerna1,2*, John V Flores3,4, Sudeep Chawla5, Stephen M Brown6, Joseph Anderson II7, ND Victor Carsrud8,
Hilary M Holets3,4, Rashad Roberson9, Uzoamaka Nwokorie10 and Kevn D Pruitt11,12

Review Article

Volume 14 Issue 3 - 2022

A Desktop Primer and Practical Review of Cannabis-Containing Compounds and Their Entourage Effects

Nicholas A Kerna^1,2*, John V Flores^3,4, Sudeep Chawla⁵, Stephen M Brown⁶, Joseph Anderson II⁷, ND Victor Carsrud⁸, Hilary M Holets^3,4, Rashad Roberson⁹, Uzoamaka Nwokorie¹⁰ and Kevn D Pruitt^11,12

¹SMC, Medical Research, Thailand

²First InterHealth Group, Thailand

³Beverly Hills Wellness Surgical Institute, USA

⁴Orange Partners Surgicenter, USA

⁵Chawla Health & Research, USA

⁶International University of Health Sciences, St. Kitts

⁷International Institute of Original Medicine, USA

⁸Lakeline Wellness Center, USA

⁹Georgetown American University, College of Medicine, Guyana

¹⁰University of Washington, USA

¹¹Kemet Medical Consultants, USA

¹²PBJ Medical Associates, LLC, USA

*Corresponding Author: Nicholas A Kerna, (mailing address) POB47 Phatphong, Suriwongse Road, Bangkok, Thailand 10500.

Received: November 19, 2021; Published: February 28, 2022

Abstract

Cannabis sativa is one of the first domesticated plants known to humankind for its numerous psychological, physical, and emotional benefits. Its first use was reported in 2600 BCE in Chinese Pharmacopoeias. Cannabis subspecies hemp and marijuana are widely studied extracts. It is a complex plant with specific constituents acting synergistically. The discovery of the plant’s numerous compounds led to another discovery—that of the endocannabinoid system (ECS), which is widely distributed in the human brain and body. The ECS is responsible for various physiological and psychological effects. However, an increase in epidemiological studies is associated with dose-increasing psychotic disorders, raising significant concern among researchers and physicians. Research began on hundreds of cannabinoids contained in the cannabis plant, leading to the detection of CB1 and CB2 receptors—following the characterization of the ECS in the human body. Specific chemicals express synergistic effects, known particularly as “entourage effects”. The concerted effect of chemical constituents of cannabis enhance the overall pharmacological properties of the plant. This entourage effect has been supported by various studies. However, a few studies debunk the construct of cannabis’ entourage effects. Recent changes in the US FDA Legalization and Scheduled Drug Act are facilitating research on the cannabis plant and compounds to explore therapeutic potential.

Keywords: Cannabidiol; Cannabinol; GABA; Phytocannabinoids; Sativa; Sleep Disorder; Terpenes; Tetrahydrocannabinol

References

Maroon J and Bost J. “Review of the neurological benefits of phytocannabinoids”. Surgical Neurology International 1 (2018). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938896/
Atakan Z. “Cannabis, a complex plant: different compounds and different effects on individuals”. Therapeutic Advances in Psychopharmacology 6 (2012): 241. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736954/
Hanuš LO and Hod Y. “Terpenes/Terpenoids in Cannabis: Are They Important?” Medical Cannabis and Cannabinoids 1 (2020): 25-60. https://www.karger.com/Article/FullText/509733
Crocq M-A. “History of cannabis and the endocannabinoid system”. Dialogues in Clinical Neuroscience 3 (2020): 223. https://pubmed.ncbi.nlm.nih.gov/33162765/
Lancet JR-T. undefined. On the therapeutical uses and toxic effects of cannabis indica (1890).
Final Act of The United Nations Conference.
Small E and Cronquist A. “A Practical And Natural Taxonomy For Cannabis”. Taxon 4 (1976): 405-435. https://www.jstor.org/stable/1220524
A H., et al. “The medicinal use of cannabis and cannabinoids--an international cross-sectional survey on administration forms”. Journal of Psychoactive Drugs 3 (2013): 199-210 https://pubmed.ncbi.nlm.nih.gov/24175484/.
Wood T., et al. J of the, 1899 undefined. III.-Cannabinol. Part I (1899).
R M LH. “A historical overview of chemical research on cannabinoids”. Chemistry and Physics of Lipids 1-2 (2000): 1-13. https://www.sciencedirect.com/science/article/abs/pii/S0009308400001845
Mechoulam R., et al. “The structure of Cannabidiol”. Tetrahedron12 (1963): 2073-2078. https://pubmed.ncbi.nlm.nih.gov/5879214/
Gaoni Y and Mechoulam R. “Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish”. Journal of the American Chemical Society8 (1964): 1646-1647. https://pubs.acs.org/doi/10.1021/ja01062a046
Ladha KS., et al. “Understanding the Medical Chemistry of the Cannabis Plant is Critical to Guiding Real World Clinical Evidence”. Molecules18 (2020). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7570835/
Maroon J and Bost J. “Review of the neurological benefits of phytocannabinoids”. Surgical Neurology International1 (2018). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938896/
Radwan MM., et al. “Cannabinoids, Phenolics, Terpenes and Alkaloids of Cannabis”. Molecules9 (2021): 2774. https://pubmed.ncbi.nlm.nih.gov/34066753/
Bautista JL., et al. “Flavonoids in Cannabis sativa: Biosynthesis, Bioactivities, and Biotechnology”. ACS Omega8 (2021): 5119. https://pubs.acs.org/doi/10.1021/acsomega.1c00318
Andre CM., et al. “Cannabis sativa: The Plant of the Thousand and One Molecules”. Frontiers in Plant Science (2016): 19. https://www.frontiersin.org/articles/10.3389/fpls.2016.00019/full
Worth T. “Cannabis’s chemical synergies”. Nature 7771 (2019): S12-S13. https://www.nature.com/articles/d41586-019-02528-1
Ben-Shabat S., et al. “An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity”. European Journal of Pharmacology 1 (1998): 23-31. https://www.researchgate.net/publication/222303665_An_entourage_effect_inactive_endogenous_fatty_acid_glycerol_esters_enhance_2-arachidonoyl-glycerol_cannabinoid_activity
Cather JC and Cather JC. “Cannabidiol primer for healthcare professionals”. Proceedings (Baylor University Medical Center) 3 (2020): 376. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340472/
Volkow ND., et al. “Adverse Health Effects of Marijuana Use”. The New England Journal of Medicine 23 (2014): 2219. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827335/
Golombek P., et al. “Conversion of Cannabidiol (CBD) into Psychotropic Cannabinoids Including Tetrahydrocannabinol (THC): A Controversy in the Scientific Literature”. Toxics 2 (2020). https://pubmed.ncbi.nlm.nih.gov/32503116/
Morales P., et al. “Molecular Targets of the Phytocannabinoids-A Complex Picture”. Progress in the Chemistry of Organic Natural Products 103 (2017): 103. https://pubmed.ncbi.nlm.nih.gov/28120232/
Russo EB. “Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects”. British Journal of Pharmacology7 (2011): 1344. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165946/
Jakowiecki J., et al. “Allosteric modulation of the cb1 cannabinoid receptor by cannabidiol-a molecular modeling study of the n-terminal domain and the allosteric-orthosteric coupling”. Molecules9 (2021). https://pubmed.ncbi.nlm.nih.gov/33922473/
Vučković S., et al. “Cannabinoids and Pain: New Insights From Old Molecules”. Frontiers in Pharmacology (2018): 1259. https://pubmed.ncbi.nlm.nih.gov/30542280/
Reggio PH. “Endocannabinoid Binding to the Cannabinoid Receptors: What Is Known and What Remains Unknown”. Current Medicinal Chemistry14 (2010): 1468. https://pubmed.ncbi.nlm.nih.gov/20166921/
Søes I., et al. “Cannabinoid CB1 and CB2 Receptor Signaling and Bias 2.1 (2017): 48-60. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436336/
Whiting PF., et al. “Cannabinoids for Medical Use: A Systematic Review and Meta-analysis”. JAMA: The Journal of the American Medical Association 24 (2015): 2456-2473. https://pubmed.ncbi.nlm.nih.gov/26103030/
Jugl S., et al. “A systematic review of evidence for cannabis and cannabinoids as adjuvant therapy in palliative and supportive oncology care 38.15 (2020): 12091-12091. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.12091
V M., et al. “Topical cannabis-based medicines - A novel adjuvant treatment for venous leg ulcers: An open-label trial”. Experimental Dermatology9 (2021): 1258-1267. https://pubmed.ncbi.nlm.nih.gov/34013652/
A practical approach to utilizing cannabis as adjuvant therapy in inflammatory bowel disease | GI and Hepatology News (2021). https://www.mdedge.com/gihepnews/article/228055/ibd-intestinal-disorders/practical-approach-utilizing-cannabis-adjuvant/page/0/2
BG R., et al. “Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation”. The Journal of neuroscience: the official journal of the Society for Neuroscience8 (2005): 1904-1913. https://pubmed.ncbi.nlm.nih.gov/15728830/
MM B., et al. “Safety and side effects of cannabidiol, a Cannabis sativa constituent”. Current Drug Safety4 (2011): 237-249. https://pubmed.ncbi.nlm.nih.gov/22129319/
Johnson JR., et al. “Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC: CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain”. Journal of Pain and Symptom Management2 (2010): 167-179. https://pubmed.ncbi.nlm.nih.gov/19896326/
Lewis MA., et al. “Pharmacological Foundations of Cannabis Chemovars”. Planta Medica04 (2017): 225-233. https://pubmed.ncbi.nlm.nih.gov/29161743/
Baron EP., et al. “Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort”. The Journal of Headache and Pain1 (2018): 1-28. https://pubmed.ncbi.nlm.nih.gov/29797104/
Fukumoto S., et al. “Effect of flavour components in lemon essential oil on physical or psychological stress”. Stress and Health1 (2008): 3-12. https://onlinelibrary.wiley.com/doi/abs/10.1002/smi.1158
Some of the Parts: Is Marijuana’s “Entourage Effect” Scientifically Valid? - Scientific American (2021).
Raup-Konsavage WM., et al. “Cannabidiol (CBD) Oil Does Not Display an Entourage Effect in Reducing Cancer Cell Viability in vitro”. Medical Cannabis and Cannabinoids2 (2020): 95-102. https://www.karger.com/Article/Abstract/510256
Santiago M., et al. “Absence of Entourage: Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Functional Activity of Δ9-THC at Human CB1 and CB2 Receptors”. Cannabis and Cannabinoid Research3 (2019): 165. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6757242/
Van Bakel H., et al. “The draft genome and transcriptome of Cannabis sativa”. Genome Biology10 (2011):1-18. https://genomebiology.biomedcentral.com/articles/10.1186/gb-2011-12-10-r102
Russo EB. “The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis: No “Strain,” No Gain”. Frontiers in Plant Science (2019): 1969. https://www.frontiersin.org/articles/10.3389/fpls.2018.01969/full
Booth JK., et al. “Terpene synthases from Cannabis sativa”. Plos One3 (2017): e0173911. https://pubmed.ncbi.nlm.nih.gov/28355238/
SJ W JBJE J. “Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report”. Archives of General Psychiatry6 (2000): 547-552. https://pubmed.ncbi.nlm.nih.gov/10839332/

Citation: Kerna NA, Flores JV, Chawla S, Brown SM, Anderson II J, Carsrud NDV, Holets HM, Roberson R, Nwokorie U, Pruitt KD. “A Desktop Primer and Practical Review of Cannabis-Containing Compounds and Their Entourage Effects”. EC Neurology 14.3 (2022): 49-57.

Copyright: © 2022 Nicholas A Kerna., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.